Open AccessDisease progression of 213 patients hospitalized with Covid-19 in the Czech Republic in March–October 2020: An exploratory analysis
Author(s) -
Martin Modrák,
Paul - Christian Bürkner,
Tomáš Sieger,
Tomás Slisz,
Martina Vašáková,
Grigorij Mesežnikov,
Luis Fernando Casas-Mendez,
Jaromír Vajter,
J Táborský,
Viktor Kubricht,
Daniel Suk,
Jan Horejsek,
M. Jedlička,
Adriana Mifková,
Adam Jaroš,
Miroslav Kubiska,
Jana Váchalová,
Robin Šín,
Markéta Veverková,
Zbysek Pospísil,
Julie Vohryzková,
Rebeka Pokrievková,
Kristián Hrusák,
Kristína Christozova,
Vianey LeosBarajas,
Karel Fišer,
Tomáš Hyánek
Publication year - 2021
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0245103
Subject(s) - azithromycin , favipiravir , hydroxychloroquine , medicine , covid-19 , disease , pandemic , intensive care medicine , emergency medicine , biology , infectious disease (medical specialty) , microbiology and biotechnology , antibiotics
We collected a multi-centric retrospective dataset of patients (N = 213) who were admitted to ten hospitals in Czech Republic and tested positive for SARS-CoV-2 during the early phases of the pandemic in March—October 2020. The dataset contains baseline patient characteristics, breathing support required, pharmacological treatment received and multiple markers on daily resolution. Patients in the dataset were treated with hydroxychloroquine (N = 108), azithromycin (N = 72), favipiravir (N = 9), convalescent plasma (N = 7), dexamethasone (N = 4) and remdesivir (N = 3), often in combination. To explore association between treatments and patient outcomes we performed multiverse analysis, observing how the conclusions change between defensible choices of statistical model, predictors included in the model and other analytical degrees of freedom. Weak evidence to constrain the potential efficacy of azithromycin and favipiravir can be extracted from the data. Additionally, we performed external validation of several proposed prognostic models for Covid-19 severity showing that they mostly perform unsatisfactorily on our dataset.